With 1.21 million shares changed hands, the volume of the stock remained heavier than its average volume of 84770.0 shares. During the session, the Health Information Services company that operates in wider Healthcare sector, reached to the highest price of $45.41 whereas the lowest price it dropped to was $42.375. The 52-week range on CTEV shows that it touched its highest point at $43.83 and its lowest point at $4.80 during that stretch. It currently has a 1-year price target of $31.33. Beta for the stock currently stands at 0.54.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of CTEV was up-trending over the past week, with a rise of 8.95%, but this was up by 63.47% over a month. Three-month performance surged to 98.45% while six-month performance rose 593.95%. The stock gained 194.86% in the past year, while it has gained 204.76% so far this year. A look at the trailing 12-month EPS for CTEV yields -72.94 with Next year EPS estimates of -11.15. For the next quarter, that number is -1.45. This implies an EPS growth rate of 85.35% for this year and 25.33% for next year.
Float and Shares Shorts:
At present, 16.44 million CTEV shares are outstanding with a float of 7.30 million shares on hand for trading. On 2025-06-13, short shares totaled 0.43 million, which was 263.00002 higher than short shares on 1747267200. In addition to Mr. Travis S. Dalton as the firm’s CEO, President & Chairman, Mr. Douglas M. Garis serves as its Executive VP & CFO.
Institutional Ownership:
Through their ownership of 0.82254 of CTEV’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-03-31, CTEV reported revenue of $231330000.0 and operating income of $9742000.0. The EBITDA in the recently reported quarter was $121769000.0 and diluted EPS was -$4.38.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential. With CTEV analysts setting a high price target of 44.0 and a low target of 25.0, the average target price over the next 12 months is 34.5. Based on these targets, CTEV could surge 0.96% to reach the target high and fall by -42.63% to reach the target low. Reaching the average price target will result in a decline of -20.84% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$80.31484 being high and -$81.11298 being low. For CTEV, this leads to a yearly average estimate of -$80.71391.
